Sina J Torabi, Milind Vasudev, Ashley Lonergan, Timothy I Hsu, Poonam P Dalwadi, Brian J F Wong, Edward C Kuan
Objectives: To evaluate trends in botulinum toxin (BTX) industry payments to physicians. Methods: Cross-sectional analysis of nonroyalty, BTX-specific payments made by Allergan (Botox), Ipsen (Dysport), and Merz (Xeomin) to physicians using the 2016-2020 Open Payments Database. Results: Between 2016 and 2020, >$27 million in payments was made for BTX-related activities to dermatologists, neurologists, ophthalmologists, otolaryngologists, and plastic surgeons, with payments ranging from $3.9 million in 2016 to $8...
March 26, 2024: Facial plastic surgery & aesthetic medicine